Perspective Therapeutics, Inc. SEC Filings

BlackRock, Inc. reports beneficial ownership of 5,251,363 shares of Perspective Therapeutics Inc. common stock, representing 4.6% of the class as disclosed in this Amendment No. 1 to Schedule 13G/A. The report attributes holdings to certain Reporting Business Units of BlackRock and is signed on 04/27/2026.

Perspective Therapeutics reported updated interim results from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with advanced SSTR2-positive neuroendocrine tumors. As of the March 4, 2026 data cut-off, 64 patients had received at least one treatment across three dose cohorts.

The company highlighted a favorable safety profile with no dose-limiting toxicities, no Grade 4 or 5 adverse events, no treatment-related discontinuations, and no serious renal complications or clinically significant treatment-related myelosuppression. Grade 3 or higher treatment-emergent adverse events occurred in 23 patients, and one previously reported Grade 4 lymphopenia was revised to Grade 3.

Among two patients in Cohort 1 and 23 in Cohort 2, 18 of 25 patients (72%) were alive without progression, and 10 of 23 Cohort 2 patients (43%) had objective responses by investigator-assessed RECIST v1.1, with several showing deepening responses over time. Perspective plans further data updates in 2026 and continued regulatory engagement.

Perspective Therapeutics has issued its 2026 proxy for the Annual Meeting to be held on May 27, 2026 at 9:00 a.m. Central Time in Chicago. Stockholders of record as of April 2, 2026, when 114,017,755 common shares were outstanding, may vote.

Investors are asked to elect six directors for one-year terms, ratify WithumSmith+Brown, PC as independent auditor for 2026, and choose how often to hold advisory votes on executive pay. The Board recommends voting “FOR ALL” director nominees, “FOR” auditor ratification, and “1 YEAR” for the say‑on‑frequency proposal.

Perspective Therapeutics filed a Form 8-K to note that it has updated its corporate presentation, which is attached as Exhibit 99.1. The presentation highlights its focus on next-generation radiopharmaceuticals built on a proprietary lead-212 (212Pb) radioligand platform designed to optimize the therapeutic index and targeted tumor delivery.

The company outlines a wholly owned 212Pb-based oncology portfolio, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma targeting MC1R, and PSV359 targeting FAP-α in solid tumors. Early Phase 1/2a trials are described as showing anti-tumor activity and favorable tolerability, with Phase 1/2 data expected across all three programs in 2026.

Perspective Therapeutics, Inc. describes its business as a clinical-stage radiopharmaceutical company developing precision targeted alpha therapies for cancer. Its platform centers on Lead‑212 (212Pb) therapeutics paired with Lead‑203 (203Pb) imaging to personalize treatment and limit damage to healthy tissue.

The company’s lead programs target neuroendocrine tumors (VMT‑α‑NET), metastatic melanoma (VMT01) and FAP‑α–expressing solid tumors (PSV359), all in Phase 1/2a trials. It highlights Fast Track designations, early clinical signals, and a 2024 option and funding agreement with an affiliate of Lantheus for VMT‑α‑NET and earlier PSMA/GRPR assets.

Perspective is building a distributed manufacturing network using proprietary 212Pb generators, facilities in Iowa and New Jersey, and new sites in Houston, Chicago and Los Angeles. The filing emphasizes substantial ongoing losses, the need for significant additional capital, clinical, regulatory and manufacturing risks, and stock price volatility. As of March 12, 2026, common shares outstanding were 113,933,436.

Perspective Therapeutics reported a larger net loss for 2025 while advancing its radiopharmaceutical pipeline and strengthening its balance sheet. Net loss was $103.1 million, or $1.40 per share, compared with $79.3 million, or $1.23 per share in 2024, driven mainly by higher research and development spending.

Research and development expenses rose to $84.2 million, up about 102%, as the company expanded clinical activities for its VMT-α-NET, VMT01 and PSV359 programs and recorded a $10.0 million non-cash impairment on a deprioritized preclinical asset. General and administrative expenses increased to $30.2 million from $26.6 million.

Cash, cash equivalents and short-term investments were about $145 million as of December 31, 2025, down from $227 million a year earlier. In February 2026, the company closed an underwritten equity offering with net proceeds of approximately $164 million, and now expects its cash resources to fund planned clinical milestones and operations into late 2027.

Perspective Therapeutics, Inc. ownership disclosure: Avidity reporting group states shared beneficial ownership of 6,049,999 shares of Common Stock, representing 5.3%.

The filing also shows Avidity Private Master Fund I LP holds 5,849,999 shares ( 5.1%). The report is signed by Michael Gregory on 03/10/2026.

Perspective Therapeutics director Maria E. Martinez received a grant of stock options, giving her the right to buy 50,000 shares. The award, approved by the board as her annual 2026 equity grant, was granted on March 2, 2026 and carries a zero exercise price. The option vests in full on March 2, 2027, as long as she continues serving through that date.

Morich Frank reported acquisition or exercise transactions in this Form 4 filing.

Perspective Therapeutics, Inc. director Frank Morich received a grant of stock options covering 50,000 shares as his annual equity award for 2026. The Board of Directors approved the grant on January 26, 2026, with a grant date of March 2, 2026.

The option vests in full on March 2, 2027, provided Morich continues to serve through that date. Following this grant, he holds 50,000 stock options directly, reflecting a standard equity compensation award rather than an open-market share purchase or sale.